<DOC>
	<DOC>NCT01613079</DOC>
	<brief_summary>Evaluation of oral T2 (chloroform/methanol extract of Tripterygium wilfordii Hook F) in the treatment of RA patients with clinical efficacy and safety.Open-labeled, randomized, prospective multi-center clinical trial. Observation period of 24 weeks.</brief_summary>
	<brief_title>Efficacy and Safety of Tripterygium Wilfordii in Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Age 1865 years with informed consent Diagnosed with rheumatoid arthritis as determined by meeting the 2010 ACR/EULAR classification criteria and has had rheumatoid arthritis for at least 6 weeks Swollen joint (SJC)≥3 and tender joint count(TJC)≥5 ESR &gt;28 mm/hr or Creactive protein &gt; 20 mg/L Pregnant, lactating or further fertility requirements Previous treated with methotrexate or biologic DMARD. Active or chronic infection, including HIV, HCV, HBV, tuberculosis Patient with cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Tripterygium</keyword>
</DOC>